During a live virtual event, Ann LaCasce, MD, MMSc, discusses third-line treatment options for diffuse large B-cell lymphoma when considering eligibility for chimeric antigen receptor T-cell therapy.
CD19-Directed Antibody-Drug Conjugates for DLBCL
During a live virtual event, Paolo Caimi, MD, discussed the barriers to using loncastuximab tesirine for diffuse large B-cell lymphoma preceding chimeric antigen receptor T-cell therapy.
During a live virtual event, Paolo Caimi, MD, discussed the toxicity and dosage of loncastuximab tesirine as a third-line therapy for diffuse large B-cell lymphoma before receiving chimeric antigen receptor T-cell therapy.
During a live virtual event, Paolo Caimi, MD, discussed third-line treatment of a patient with diffuse large B-cell lymphoma and navigating obstacles to treatment.
During a live virtual event, Beth A. Christian, MD, discussed data on third-line loncastuximab tesirine treatment in patients with diffuse large B-cell lymphoma and how to sequence treatments for patients who may receive CAR T-cell therapy.
During a live virtual event, Beth A. Christian, MD, discussed real-world challenges of providing timely access to CAR-T cell therapy for patients with diffuse large B-cell lymphoma.
During a live virtual event, Beth A. Christian, MD, discussed approaches to third-line treatment of transplant-ineligible DLBCL and when to consider CAR T-cell therapy.
While antibody-drug conjugates have shown promise in patients with relapsed/refractory diffuse large B-cell lymphoma, there are other options that can help patients before moving on to CAR T-cell therapy.
Justin Kline, MD, discusses what makes loncastuximab tesirine-lpyl a good bridge therapy for patients with relapsed/refractory diffuse large B-cell lymphoma to potential CAR T-cell therapy.
Looking at the challenges with CAR T-cell therapies in patients with diffuse large B-cell lymphoma Justin Kline, MD, discusses the best available therapies for patients who relapse on treatment.
The efficacy and data for the combination of polatuzumab vedotin plus bendamustine and rituximab for patients with diffuse large B-cell lymphoma show effective outcomes for patients that clinicians can use when discussing treatment options.
Looking at the combination of lenalidomide plus tafasitamab for patients with diffuse large B-cell lymphoma shows promise for patients' treatment, but challenges remain that clinicians need to address.
During a live virtual event with other physicians, Bijal Shah, MD, MS, discussed treatment options for patients with diffuse large B-cell lymphoma and the data that backs up the efficacy for these options.